[Federal Register Volume 59, Number 34 (Friday, February 18, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-3737]


[[Page Unknown]]

[Federal Register: February 18, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESS: Licensing information and copies of the U. S. patent 
applications listed below may be obtained by writing to the indicated 
Licensing Specialist at the Office of Technology Transfer, National 
Institutes of Health, Box OTT, Bethesda, Maryland 20892 (telephone 301/
496-7735; fax 301/402-0220). A signed Confidentiality Agreement will be 
required to receive copies of the patent applications. Issued patents 
may be obtained from the Commissioner of Patents, U.S. Patent and 
Trademark Office, Washington, DC 20231.

Modification of Hepatitis B Virus Infection in Chronic Carriers of 
Hepatitis B Surface Antigens

Gerin, J.L., Levy, H.B., Merigan, T.C., Purcell, R.H. (NIAID)
Serial No. 05/786,202 filed 11 Apr 77
U.S. Patent 4,140,761 issued 20 Feb 79
Licensing Contact: Girish C. Barua

    Interferon introduced parenterally in a human host or stimulated by 
an inducer (PICLC) for a period of greater than 21 days results in 
major decrease in all markers of infectivity, such as DNA polymerase, 
and such markers remain at a depressed level during the period of 
treatment. Long-term treatment with exogenous interferon of greater 
than 21 days and up to 14 months results in clinical improvement for 
chronic hepatitis B virus (HBV) infection and this long-term treatment 
has resulted in sustained improvement even after cessation of treatment 
as well as resulting in decrease in infectivity risk to others in close 
proximity to the infected human host.

Detection of Non-B Hepatitis Associated Antigens

Tabor, E., Gerety, R.J. (FDA)
Serial No. 06/040,921 filed 21 May 79
U.S. Patent 4,356,164 issued 26 Oct 82
Licensing Contact: Girish C. Barua

    A method to detect highly transmittable agent of non-A, non-B 
hepatitis using a counterelectrophoresis analysis. The method may also 
be applied in the recipients of blood transfusion and for screening 
blood donors where the donor had transmitted by transufison non-A, non-
B hepatitis antigens several years previously.

Detection of Non-A, Non-B Hepatitis Associated Antigens

Tabor, E., Gerety, R.J. (FDA)
Serial No. 06/319,995 filed 10 Nov 81 [CIP of 06/192,291 (ABAN),
CIP of 06/060,921]
U.S. Patent 4,395,395 issued 26 Jul 83
Licensing Contact: Girish C. Barua

    In the detection of transmittable agent of non-A, non-B hepatitis a 
method is described in this invention utilizing antigen-antibody 
reaction and preferred counterelectrophoresis technique for detection 
of said antigen.

Heat Treatment of Non-A, Non-B Hepatitis Agent To Prepare a Vaccine

Tabor, E., Gerety, R.J. (FDA)
Serial No. 06/343,026 filed 27 Jan 82
U.S. Patent 4,438,098 issued 20 Mar 84
Licensing Contact: Girish C. Barua

    A method of treating the agent of human non-A, non-B hepatitis to 
render it incapable of causing infection which comprises heating said 
agent at about 60 deg. C for about 10 hours and recovering the treated 
protective agent, which could be utilized as a vaccine.

Screening Test for Reverse-Transcriptase Containing Virus Such as Non-
A, Non-B Hepatitis, NANBH

Seto, B.P., Gerety, R.J., Coleman, W.G. (FDA)
Serial No. 06/665,400 filed 26 Oct 84
U.S. Patent 4,707,439 issued 17 Nov 87
Licensing Contact: Girish C. Barua

    The invention covers a screening test for detecting the presence of 
contaminating or infectious agents causing non-A, non-B hepatitis or 
AIDS in a blood donor setting. A kit for detecting contaminating agents 
belongs to retrovirus is also disclosed. Screening blood or blood 
related products so as to prevent spreading of infection or 
contamination due to retroviruses is now possible by the present 
invention.

Purified Antigens From Non-A, Non-B Hepatitis Causing Factor

Seto, B., Gerety, R.J. (FDA)
Serial No. 06/709,678 filed 8 Mar 85
U.S. Patent 4,673,634 issued 16 Jun 87
Licensing Contact: Girish C. Barua

    The invention discloses an isolated and purified antigen specific 
to non-A, non-B hepatitis (NANBH) causing agent. The utility of the 
antigen as a diagnostic serologic marker and as screening device for 
detecting the carrier or source of non-A, non-B hepatitis or infective 
factor thereof, particularly in a blood bank or plasmapheresis setting 
and preventing transmission of NANBH by isolating the source is 
described. Use of the antigens as vaccine to induce protective 
antibodies capable of neutralizing NANBH infectivity along with a kit 
for detecting the presence or identifying the carriers or sources of 
non-A, non-B hepatitis or causative agent thereof is disclosed.

Retrovirus and Related Method Used for Producing a Model for Evaluating 
the Anti-Retroviral Effects of Drugs and Vaccines

McClure, H., Fultz, P., Anderson, D. (CDC)
Serial No. 07/200,843
U.S. Patent 5,212,084 issued 18 May 93
Licensing Contact: Steven M. Ferguson

    An HIV-like retrovirus (SIV/SMM) isolated from clinically normal 
sooty mangabey monkeys provides a rapid means of testing the efficacy 
of newly developed anti-retroviral drugs and vaccines. These methods 
are based upon the observation that SIV/SMM has been shown to cause 
persistent infection and clinical AIDS-like disease when inoculated 
into rhesus monkeys and pigtailed macaques. Upon collection and re-
inoculation into simians seronegative for SIV/SMM, acute clinical 
disease appears in all recipients within 3 to 5 days that progresses to 
death shortly thereafter.

A Sensitive Diagnostic Test for Lyme Disease

Rosa, P.A., Schwan, T.G. (NIAID)
Serial No. 07/885,077 [FWC of 07/361,850 (ABAN)]
Filed 18 May 92
Licensing Contact: Girish C. Barua

    The nucleotide sequence of a recombinant clone containing a 
specific segment of Borrelia burgdorferi DNA which enables the 
identification of the spirochetes causing Lyme disease has been 
provided. A diagnostic kit containing oligonucleotide primers derived 
from this sequence, suitable for the detection of Borrelia burgdorferi 
in a PCR assay, as well as the cloned DNA of the present invention, 
allows the detection of Lyme disease sprockets with sensitivity and 
specificity not heretofore attained by any other test.

Clones Encoding Mammalian ADP-Ribosylarginine Hydrolases

Moss, J., Stanley, S.J., Nightingale, M.S., Murtagh, J.J.,
Monaco, L., Takada, T. (NHLBI)
Serial No. 07/888,231
Filed 22 May 92
Licensing Contact: Girish C. Barua

    The invention relates to the production of mammalian ADP-
ribosylarginine hydrolases. These enzymes can be synthesized using 
recombinant DNA technology. The enzymes catalyze the removal of the 
ADP-ribose moiety from protein and regulate the ADP-ribose content of 
protein.

Specific and Sensitive Diagnostic Test for Lyme Disease

Simpson, W.J., Schwan, T., Garon, C. (NIAID)
Serial No. 07/898,233 [FWC of 07/427,735 (ABAN)]
Filed 12 Jun 92
Licensing Contact: Girish C. Barua

    This patent application describes species-specific DNA sequences in 
the pathogenic bacterium Borrelia burgdorferi. It includes the use of 
these sequences, other related sequences obtained from the bacteria, 
and similar DNA sequences generated by recombinant techniques, as DNA 
probes for the identification of B. burgdorferi. The target sequences 
have been found in multiple locations and are associated with plasmid 
molecules. Thus, the natural amplification of these target sequences 
may create a sensitivity advantage over other single-site DNA probe 
targets.

Recombinant Vaccinia Virus Expressing Human Retorvirus Gene

Moss, B., Chakrabarti, S. (NIAID)
Serial No. 07/919,384
Filed 7 Jul 89
Licensing Contact: Girish C. Barua

    A recombinant vaccinia virus carrying the HIV gp-160 env gene under 
control of the early/late vaccinia promoter P7.5 and the E. coli lacZ 
gene under control of the vaccinia P11 promoter all inserted into the 
vaccinia thymidine kinase gene was made. Cells infected with the virus 
display the HIV gp 160, gp 120 and gp 41 proteins on their surface. 
These proteins reacted with the sera from AIDS patients. The 
recombinant vaccinia virus can be used to make these proteins and also 
as a vaccine. The recombinant virus and the method of making HIV 
envelope proteins are claimed.

Method for Immune Capture and Primary Isolation of Borrelia Burgdorferi

Dorward, D.W., Schwan, T.G., Garon, C.F. (NIAID)
Serial No. 07/929,172 (CIP of 07/485,551, U.S. Patent 5,217,872 issued 
8 Jun 93)
Filed 11 Aug 92
Licensing Contact: Girish C. Barua

    This invention relates to novel antigens associated with Borrelia 
burgdorferi which are exported (or shed) in vivo and whose detection is 
a means of diagnosing Lyme disease. The antigens are extracellular 
membrane vesicles and other bioproducts including the major 
extracellular protein. The invention further provides antibodies, 
monoclonal and/or polyclonal, labeled and/or unlabeled, that react with 
the antigens. The invention is also directed to a method of diagnosing 
Lyme disease by detecting the antigens in a biological sample taken 
from a host using the antibodies in conventional immunoassay formats. 
The invention further relates to kits, for the diagnosis of Lyme 
disease, comprising the antibodies and ancillary reagents. The 
advantage of the antibodies used in the invention is that they react 
with the antigens from geographically diverse strains of Borrelia 
burgdorferi, but do not react with antigens from related Borrelia 
spirochetes.

Enzyme Immunoassay for the Detection of a Marker Associated With a 
Severe Outcome of Hepatitis Delta Virus Inspection

Fields, H.A., Khudyakov, Y. (CDC)
Serial No. 07/976,358
Filed 17 Nov 92
Licensing Contact: Girish C. Barua

    This invention is a method of predicting the development of severe 
forms of hepatitis delta virus infection (HDV infection) by detecting 
the presence of anti-HDAg' antibody in patients with HDV infection. The 
presence of these antibodies is associated with the more severe forms 
of HDV infection. The invention additionally encompasses an assay for 
detection of HDAg' antibodies in biological samples, and a vaccine 
comprising immunologically active HDAg' polypeptides.

Antigenic Protection of Borrelia Burgdorferi

Simpson, W.J., Schwan, T.G. (NIAID)
Serial No. 08/020,245 (FWC of 07/664,731)
Filed 19 Feb 93
Licensing Contact: Girish C. Baura

    This patent application describes a 39 Kda protein (P39) that is 
species-specific and expressed by all North American and European B. 
burgdorferi isolates. The discovery includes the cloning and expression 
of the gene for P39 in E. coli and the use of P39 as a diagnostic 
antigen for the serodiagnosis of Lyme borreliosis. The P39 described in 
this invention report has been found not only to be species-specific, 
but reactive only with human Lyme sera. This suggests that any 
patient's serum that is shown to react to P39, irrespective of the 
patient's clinical picture, can be diagnosed as having Lyme 
borreliosis.

Article and Method for Detecting the Presence of Pathogens in Excreta

Dobbins, J., Stewart, J.A., Pellett, P., Koopmans, M. (CDC)
Serial No. 08/048,807
Filed 16 Apr 93
Licensing Contact: Girish C. Barua

    The present invention provides a diagnostic diaper capable of 
selectively capturing disease causing agents, such as cytomegalovirus 
(CMV), from urine. Claims are directed to a diaper with a built in 
diagnostic assay for infection detectable in excreta, in particular, 
CMV infection in urine. This invention could be used to screen newborns 
nationally for infection with CMV since the only current method of 
detecting CMV infection is to culture the urine, an unsuitable 
procedure for national screening because of expense, the requirement of 
special handling, and delayed results.

Immortalized Human Cell Lines Containing Exogenous Cytochrome P450 
Genes

Harris, C., Gelboin, H., Gonzalez, F., Mace, L., Pfeifer, A.
(NCI)
Serial No. 08/065,201
Filed 19 May 93
Licensing Contact: Steven M. Ferguson

    Stable, non-tumorigenic human bronchial and liver epithelial cell 
lines have been developed that are capable of expressing human 
cytochrome P450 genes. These immortalized cell lines express 
enzymatically active cytochrome P450 enzymes typically involved in 
xenobiotic metabolism. Use of these cell lines makes it now possible to 
design low-cost in vitro toxicity tests or screens for food-born and 
environmental carcinogens, pathogens or mutagens. Previous toxicology 
testing methods could only be done in animals, bacteria (Ames test) or 
animal cell culture models and could not always be fully extrapolated 
to determine human risk.

Regulator of Contact-Medicated Hemolysin of Mycobacterium 
Tuberculosis

King, H.C., Sathish, M., Crawford, J.T., Schinnick, T.M. (CDC)
Serial No. 08/066,830
Filed 24 May 93
Licensing Contact: Girish C. Barua

    The present invention shows that virulent strains of M. 
tuberculosis possess hemolytical activity while avirulent strains do 
not. The invention provides the isolation of a contact hemolysin gene 
from M. tuberculosis. Claims are directed to the gene, to the protein 
produced and to antibodies specifically reactive with the protein. 
Claims are also directed to diagnostic tests for infection and tests to 
the distinguished virulent from avirulent infection.

Recombinant Disulfide-Stabilized Polypeptide Fragments Having Binding 
Specificity

Pastan, I., Lee, B., Jung, S-H, Brinkmann, U. (NCI)
Serial No. 08/077,252
Filed 14 Jun 93
Licensing Contact: Daniel R. Passeri

    The present invention relates to disulfide-stabilized recombinant 
polypeptide molecules which have the binding ability and specificity 
for another peptide, such as the variable region of an antibody 
molecule. Methods of producing these molecules and nucleic acid 
sequences encoding these molecules are also described. In particular, 
the invention discloses Fv antibody fragments stabilized by a disulfide 
bond connecting the VH and VL regions of the Fv fragment. The 
 and  chains of T cell receptors may be similarly 
stabilized by means described in the invention.

Nucleic Acids of a Novel Hantavirus and Reagents for Detection and 
Prevention of Infection

Nichol, S.T. (CDC)
Serial No. 08/084,724
Filed 24 Jun 93
Licensing Contact: Girish C. Barua

    An outbreak of acute illness in the Four-Corners region of the 
United States in the spring of 1993 has been associated with the Muerto 
Canyon strain of hantavirus. The identification of specific nucleotide 
sequence information for this virus will aid in the development of 
diagnostic assays and vaccines.

Diagnostic Reagents and Vaccines for Multiple Genotypes of Hepatitis C 
Virus

Bukh, J., Miller, R.H., Purcell, R.H. (NIAID)
Serial No. 08/086,428
Filed 29 Jun 93
Licensing Contact: Girish C. Barua

    The invention describes the complete nucleotide and deduced amino 
acid sequences of the envelope 1 (E1) gene of 51 hepatitis C virus 
(HCV) isolates from around the world and the grouping of these isolates 
into twelve distinct HCV genotypes. More specifically, this invention 
relates to the oligonucleotides, peptides and recombinant proteins 
derived from the envelope 1 gene sequences of these isolates and to 
diagnostic methods and vaccines that employ these reagents.

Poliovirus Specific Primers and Methods of Detection Utilizing the Same

Kilpatrick, D.R. (CDC)
Serial No. 08/092,110
Filed 13 Jul 93
Licensing Contact: Girish C. Barua

    The ability to rapidly detect wild polioviruses in clinical 
specimens is a major concern for the world-wide eradication of 
polioviruses. This invention describes a method of detecting 
polioviruses of all three serotypes from viral isolates of clinical 
specimens using a pair of degenerate PCR primers. These PCR primers do 
not recognize nonpoliovirus enteroviruses. All poliovirus serotypes (40 
polio vaccine-related genotypes and 120 wild poliovirus genotypes from 
around the world) tested positive. The poliovirus-specific PCR primer 
will allow for the rapid diagnosis of whether clinical cases of acute 
flaccid paralysis are the result of a poliovirus infection.

MRI Coil Having Inductively Coupled and Individually Tuned Elements 
Arranged as Free-Pivoting Components

Wen, H., Chesnick, A.S., Balaban, R.S. (NHLBI)
Serial No. 08/104,849
Filed 12 Aug 93
Licensing Contact: John Fahner-Vihtelic

    This application describes an MRI probe/transmitter coil that is 
composed of concentric cylinders with resonant elements. The probe/
transmitter can be tuned using a plurality of freely rotating resonant 
elements radially mounted between the two cylinders. This invention 
reduces the effects of subject characteristic variations on the coil 
resonant frequency in an MRI system. Further, this apparatus increases 
the sensitivity and efficiency in the magnetic resonance system by 
raising the Q factor of the probe coil/transmitter. Prototype apparatus 
effectively reduces the significant coil-subject coupling at high 
frequencies.

Novel and Selective Inhibitors of Biogenic Amine Transporters

Rothman, R.B., Carroll, F.I., Blough, B., Mascarella, S.W. (NIDA)
Serial No. 08/105,747
Filed 12 Aug 93
Licensing Contact: Arthur Cohn

    Novel compounds, particularly (2RS, 3aSR, 8aRS)-1,2,3a,8,8a-
Hexahydro-2-Benzyl-1-Methyl-Indeno[1,2-b]pyrrole, bind selectively and 
potently to the PCP site 2 associated with biogenic amine transporters 
(BAT), and block these transporters. This compound is the first high 
affinity ligand to be described which clearly distinguishes between the 
two PCP binding sites. It differs from phencyclidine (PCP) in that: (1) 
It has no activity at the MK801-sensitive NMDA receptor, (2) it has 
considerably higher affinity for the norepinephrin transporter, and (3) 
it does not produce PCP-like behavioral effects in rats. The compound 
has been shown to raise the extracellular dopamine levels in rats. Thus 
it may have utility in treating conditions, like Parkinsons Disease and 
depression, that respond to increased dopamine levels. Radiolabeled 
compounds of the invention are useful to label PCP site 2.

Method for Proton Magnetic Resonance Spectroscopie Imaging With 
Multiple Spin-Echoes

Moonen, C.T., Duyn, J. (NCRR)
Serial No. 08/106,377
Filed 13 Aug 93
Licensing Contact: John Fahner-Vihtelic

    This application describes a new method for proton magnetic 
resonance spectroscopic imaging. This new method does not have the 
limiting disadvantages of the previous techniques. The method combines 
multi-slice and multi-spin-echo techniques for high signal-to-noise 
ratio per unit time and high efficiency spectroscopic information. This 
invention can also produce compound weighted spectroscopic images by 
selecting the period between refocusing pulses according to the 
coupling constant of a group contained in the compound. Application of 
a pulse sequence to conventional MRI imaging apparatus allows for rapid 
acquisition of data for generating spectroscopic images.

Orally Active Derivatives of 1,3,5(10)-Estratriene

Kim, H.K, Blye, R.P., Bialy, B. (NICHD)
Serial No. 08/122,853
Filed 17 Sep 93
Licensing Contact: Carol C. Lavrich

    Newly developed esters of estradiol which exhibit potent oral and 
parenteral estrogenic activity offers a new therapy for replacement of 
the natural hormone, estradiol, in hypogonadism and following removal 
of the ovaries or cessation of ovarian activity during menopause. The 
natural hormones, estradiol and estrone are only weakly active upon 
oral administration requiring large dosages. The most frequently used 
oral estrogen, 17-alpha-ethenylestradiol, has been associated with a 
number of serious dose-related side effects. The novel estrogens of 
this patent, lack the ``ethynyl'' group and can be used in lower doses, 
thus eliminating the side effects. The compounds are particularly 
suitable for use as the estrogenic component of combined oral 
contraceptives.

Binding Domains From Plasmodium Vivax and Plasmodium Falciparum 
Erythrocyte Binding Proteins

Sim, K.L, Chitnis, C., Miller, L.H. (NIAID)
Serial No. 98/119,677
Filed 10 Sep 93
Licensing Contact: Mark D. Hankins

    Despite considerable research efforts worldwide it has not been 
possible to design an effective vaccine against malaria. The present 
invention provides the basis for an effective vaccine against the blood 
state of malaria infections.
    This invention relates to the identification of functional domains 
of Plasmodium proteins which play a role in erythrocyte binding and 
invasion. The inventors have identified the erythrocyte binding domains 
of the sialic acid binding protein (SABP) of P. falciparum and the 
Duffy antigen binding protein (DABP) of P. vivax. The erythrocyte 
binding domains can be used as vaccines to induce immune responses 
which block erythrocyte binding and invasion by P. falciparum and P. 
vivax merozoites.

Glucose-6-Phosphatase: The Gene Protein and Related Mutations

Chou, J.Y., Lei, K.J. (NICHD)
Serial No. 08/119,773
Filed 10 Sep 93
Licensing Contact: Carol C. Lavrich

    This invention describes nucleic acid sequences and methods useful 
for producing recombinant glucose-6-phosphatase (c-6-Pase), an enzyme 
normally present in the liver, kidney, and intestine and needed in 
glycogen metabolism. Specific mutations in the gene human c-6-Pase 
cause a shortage or an inactivity of c-6-Pase which results in glycogen 
storage disease (GSD), type 1A. The invention further provides a kit 
and methods for detecting the mutations and thus diagnosing the genetic 
disease that caused GSD type 1A.

Method for Genetating Influenza A Viruses Bearing Attenuating Mutations 
in Internal Protein Genes

Murphy, B., Lawson, C.M., Subbarao, K.E. (NIAID)
Serial No. 08/123,933
Filed 20 Sep 93
Licensing Contact: Mark D. Hankins

    This patent application describes a method of producing attenuated 
Influenza A strains for use as live Influenza A virus vaccine 
candidates. The method involves the introduction of one or more 
attenuating mutations in the polymerase basic protein 2 (PB2) gene of 
Influenza A virus. The attenuating mutations introduced to date are 
temperature-sensitive mutations. These mutations are introduced by site 
directed mutagenesis at specific sites into a cDNA copy of the PB2 
gene. An RNA transcript of this mutant PB2 gene is recovered into an 
infectious influenza A virus using a host range restricted helper 
virus. This attenuating mutant PB2 gene can be transferred to each new 
variant of influenza A virus as it appears in nature. Modifications of 
this technology permits introduction of mutations into: Polymerase 
basic protein 1 (PB1) genes; polymerase acidic protein (PA) genes; 
nuclear protein (NP) genes; membrane protein (M) genes; and non-
structural protein (NS) genes. The patent application covering this 
invention is available for licensing and contains claims to: The 
methods of producing the attenuated strains; the attenuated strains 
produced by the methods; and methods of vaccination using the 
attenuated strains. Viruses containing mutant PB2 genes are also 
available for licensing.

A Predictive Assay for Suicidal Behavior

Nielsen, D.A., Goldman, D., Linnoila, M., Virkkunen, M. (NIAAA)
Serial No. 08/125,628
Filed 22 Sep 93
Licensing Contact: Arthur Cohn

    The present invention describes methods for predicting suicidal and 
other abnormal behaviors. In particular, the methods are directed to 
the detection of polymorphisms in the tryptophan hydroxylase gene which 
are correlated with abnormal serotoninergic function and related 
behaviors. Serotoninergic activity is correlated with the concentration 
of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in the 
cerebrospinal fluid (CSF). Indices of decreased serotonin concentration 
are connected with anxiety related intolerance to delay and deficient 
control of impulses. Low concentrations of 5-HIAA in the CFS have been 
associated with risk of suicide in alcoholic, antisocial, and depressed 
patients. However, the concentration of CSF 5-HIAA's usefulness as a 
marker is limited by the difficulty and expense of obtaining CSF. This 
invention fulfills the need for an easily typed marker that is 
correlated with 5-HIAA concentration and suicidal behavior.

Target Antigens of Transmission Blocking Antibodies for Malaria 
Parasites

Kaslow, D.C., Duffy, P.E. (NIAID)
DHHS Reference No. E-149-92/1
Filed 22 Sep 93
Licensing Contact: Mark D. Hankins

    This patent application is a continuation of U.S. Patent 
Application 07/912,294 which described Pgs28 a 28 kd protein found in 
Plasmodium gallinaceum. The new application describes a unique 28 kd 
protein expressed on the surface of ookinetes of Plasmodium Falciparum 
(Pfs28). This protein is useful as a malaria transmission blocking 
vaccine. The patent application covering this invention is available 
for licensing and contains claims to: The Pfs28 protein; Pfs28's amino 
acid and nucleic acid sequences; pharmaceutical compositions containing 
the polypeptide and nucleic acid sequences; and methods of preventing 
transmission of malaria using these pharmaceutical compositions.

    Dated: February 3, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-3737 Filed 2-17-94; 8:45 am]
BILLING CODE 4140-01-M